Skip to main content
Premium Trial:

Request an Annual Quote

EditCo Bio Knockout CD4+ T-Cell Pools

EditCo Bio recently launched its Knockout CD4+ T-cell Pools for CRISPR-mediated primary T-cell editing. The product features a seven-day protocol that uses EditCo Bio's multi-guide technology to achieve efficiencies of greater than 90 percent in primary human CD4+ T cells. Post-editing, CD4+ pools maintain over 80 percent viability before cryopreservation and can expand 40-fold over 14 days, regardless of TCR stimulation, the company said. After cryo-recovery, these cell pools exhibit remarkable functional integrity, matching control cells in IL2, IFNG, and TNFA protein production post-PMA/ionomycin stimulation, EditCo added. In addition, cultured cells retain over 90 percent viability and maintain editing efficiency for at least 14 days, the company said.